Firebrick Pharma Ltd
ASX:FRE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
F
|
Firebrick Pharma Ltd
ASX:FRE
|
AU |
|
O
|
Olympic Circuit Technology Co Ltd
SSE:603920
|
CN |
|
S
|
Seagate Technology Holdings PLC
XBER:847
|
SG |
|
Indian Oil Corporation Ltd
NSE:IOC
|
IN |
|
Qingdao Vland Biotech INC
SSE:603739
|
CN |
|
Y
|
Yili Chuanning Biotechnology Co Ltd
SZSE:301301
|
CN |
|
LSB Industries Inc
NYSE:LXU
|
US |
|
Dometic Group AB (publ)
STO:DOM
|
SE |
|
HITO-Communications Holdings Inc
TSE:4433
|
JP |
|
Iron Horse Acquisitions Corp
NASDAQ:IROH
|
US |
|
Saudi Telecom Company SJSC
SAU:7010
|
SA |
|
C
|
Computer and Technologies Holdings Ltd
HKEX:46
|
HK |
|
N
|
Nakamoto Packs Co Ltd
TSE:7811
|
JP |
|
S2 Resources Ltd
ASX:S2R
|
AU |
|
A
|
Allied Blenders and Distillers Ltd
NSE:ABDL
|
IN |
|
Provident Financial PLC
LSE:PFG
|
UK |
|
S
|
Shenzhen SEG Co Ltd
SZSE:000058
|
CN |
|
LG Electronics Inc
KRX:066570
|
KR |
|
P
|
Purmo Group Oyj
OMXH:PURMO
|
FI |
|
S
|
SMC Global Securities Ltd
BSE:543263
|
IN |
|
Broadwind Inc
NASDAQ:BWEN
|
US |
|
CTEEP Companhia de Transmissao de Energia Eletrica Paulista
BOVESPA:TRPL4
|
BR |
|
Canadian General Medical Centers Complex Company CJSC
SAU:9518
|
SA |
Firebrick Pharma Ltd
Firebrick Pharma Ltd. engages in the development and manufacture of pharmaceutical products. The company is headquartered in Melbourne, Victoria. The company went IPO on 2022-01-28. The firm is focused to develop Nasodine, a nasal spray that contains the broad spectrum antimicrobial agent called povidone-iodine. The firm is engaged in product formulation, packaging and manufacturing development. Nasodine nasal spray medicine targets the cause of colds, where they start in the nose. Its nasal spray is responsible for respiratory infections, such as the common cold. The firm's Series C funding, Phase III trial has been completed.
Firebrick Pharma Ltd. engages in the development and manufacture of pharmaceutical products. The company is headquartered in Melbourne, Victoria. The company went IPO on 2022-01-28. The firm is focused to develop Nasodine, a nasal spray that contains the broad spectrum antimicrobial agent called povidone-iodine. The firm is engaged in product formulation, packaging and manufacturing development. Nasodine nasal spray medicine targets the cause of colds, where they start in the nose. Its nasal spray is responsible for respiratory infections, such as the common cold. The firm's Series C funding, Phase III trial has been completed.
